Tafluprost for glaucoma

Bibliography

• Ishida N, Odani-Kawabata N, Shimazaki A, Hara H. Prostanoids in the therapy of glaucoma. Cardiovasc Drug Rev 2006;24:1-10
   PubMed Web of Science ®Google Scholar
• Camras CB, Bitlo LZ. Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2alpha. Curr Eye Res 1981;1:205-9
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu WP; XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
   PubMed Web of Science ®Google Scholar
• Noecker RS, Dirks MS, Choplin N. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2004;137:210-11
   PubMed Web of Science ®Google Scholar
• Treatment principles and options – prostaglandin derivates and prostamides. In: Heijl A, Traverso CE. editors. European Glaucoma Society, Terminology and Guidelines for Glaucoma. 3rd edition. Dogma Srl; Savona, Italy; 2008. p. 136-8
   Google Scholar
• Feldman RM. Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther 2003;19:23-35
   PubMed Web of Science ®Google Scholar
• Honrubia F, Garcia-Sanchez J, Polo V, Conjunctival hyperemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomized clinical trials. Br J Ophthalmol 2009;93:316-21
   PubMed Web of Science ®Google Scholar
• Schwartz GF. Current use of latanoprost and travoprost: a six-month, population-based cohort study. Presented as a poster session at the annual meeting of the American Glaucoma Society, 3 – 6 March 2005, Snowbird, Utah, USA
   Google Scholar
• Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004;137(Suppl):S13-16
   Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137(Suppl):S3-12
   Google Scholar
• Schwartz GF, Tan J, Kotak S. Hyperemia-associated costs of medications changes in glaucoma patients treated initially with prostaglandin analogs. J Ocul Pharmacol Ther 2009;25:555-62
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Hahn SR, Gelb L, The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009;24:49-56
   Google Scholar
• Arias A, Schargel K, Ussa F, Patient persistence with first-line antiglaucomatous monotherapy. Clin Ophthalmol 2010;4:261-7
   PubMedGoogle Scholar
• European Glaucoma Society. Treatment principles and options. In: Heijl A, Traverso CE. editors. Terminology and Guidelines for Glaucoma. 3rd edition. Dogma Srl; Savona, Italy; 2008. p. 144-5
   Google Scholar
• Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 2009;116(Suppl):S30-6
   PubMed Web of Science ®Google Scholar
• Chawla A, McGalliard JN, Batterbury M. Use of eye drops in glaucoma: how can we help to reduce non-compliance? Acta Ophthamol Scand 2007;85:464
   Google Scholar
• Zimmerman TJ, Hahn SR, Gelb L, The effect of hyperaemia on open-angle glaucoma (OAG) treatment [abstract FP-GLA-036]. Presented at the Annual Meeting of the European Society of Ophthalmology (SOE), 9 – 12 June 2007, Vienna, Austria
   Google Scholar
• Broadway DC, Grieson I, Hitchings RA. Adverse effects of topical glaucomatous medications on the conjunctiva. Br J Ophthalmol 1993;77:590-6
   PubMed Web of Science ®Google Scholar
• Schwab IR, Linberg JV, Gioa VM, Foreshortening of the inferior fornix associated with cronic glaucoma medications. Ophthalmology 1992;99:197-202
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Goldschild M, Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Human and animal studies. Ophthalmology 1999;3:556-63
   Google Scholar
• Debbash C, Pisella PJ, De Saint Jean M, Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:2525-33
   PubMed Web of Science ®Google Scholar
• Young TL, Higginbotham EJ, Zou XL, Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology 1990;97:1423-7
   PubMed Web of Science ®Google Scholar
• Turacli E, Budak K, Kaur A, The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol 1997;21:27-33
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Poliquen P, Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:341-9
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative-free glaucoma medication. Br J Ophthalmol 2002;86:418-23
   PubMed Web of Science ®Google Scholar
• Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol 2001;45:199-202
   PubMed Web of Science ®Google Scholar
• Baudouin C, de Lunardo C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 1998;82:39-42
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• Hay EM, Thomas E, Pal B, Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis 1998;57:20-4
   PubMed Web of Science ®Google Scholar
• Hollo G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 2007;6:45-52
   PubMed Web of Science ®Google Scholar
• Osborne SA, Montgomery DM, Morris D, Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye 2005;19:129-37
   PubMed Web of Science ®Google Scholar
• Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol 2004;14:407-15
   PubMed Web of Science ®Google Scholar
• Manni G, Centofanti M, Sacchetti M, Demographic and clinical factors associated with the development of brimonidine tartrate 0.2%-induced ocular allergy. J Glaucoma 2004;13:163-7
   PubMed Web of Science ®Google Scholar
• Motolko MA. Comparison of allergy rates in glaucoma patient receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%–timolol 0.5% therapy. Curr Med Res Opin 2008;24:2663-7
   PubMed Web of Science ®Google Scholar
• Mullins RJ, Lones R, Dutta B. Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Australas J Dermatol 2004;45:151-2
   PubMedGoogle Scholar
• Delaney YM, Salmon JF, Mossa F, Periorbital dermatitis as a side effect of topical dorzolamide. Br J Ophthalmol 2002;86:378-80
   PubMed Web of Science ®Google Scholar
• Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009;9:447-53
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbe A, Liang H. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 2010;29:312-34
   PubMed Web of Science ®Google Scholar
• Broadway DC, Griersin I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucomatous medications, II: the outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-54
   PubMed Web of Science ®Google Scholar
• Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 2007;18:134-9
   PubMed Web of Science ®Google Scholar
• Bensoussan L, Blondin C, Baudouin C, Flow cytomtric analysis of HLA-DR, IL-6 and IL-8 expression by conjunctival epithalial cells from patients with prolonged topical antiglaucoma tretments. J Fr Ophtalmol 2003;26:782-9
   PubMed Web of Science ®Google Scholar
• Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-26
   PubMed Web of Science ®Google Scholar
• Baudouin C. Side effects of antiglaucomtaous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7:80-6
   PubMedGoogle Scholar
• Chandrasekaran S, Cumming RG, Rochtchina E, Associations between elevated intraocular pressure and glaucoma, use of glaucoma medications, and 5-year incident cataract: the Blue Mountains Eye Study. Ophthalmology 2006;113:417-24
   PubMed Web of Science ®Google Scholar
• Nakajima T, Matsugi T, Goto W, New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull 2003;26:1691-5
   PubMed Web of Science ®Google Scholar
• Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 2001;18:287-91
   Web of Science ®Google Scholar
• Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology 1998;105:82-7
   PubMed Web of Science ®Google Scholar
• Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41:129-38
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
   PubMed Web of Science ®Google Scholar
• Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45:361-8
   PubMed Web of Science ®Google Scholar
• Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol 2001;119:614-15
   PubMed Web of Science ®Google Scholar
• Johnstone MA. Hypertricosis and increate pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7
   PubMed Web of Science ®Google Scholar
• Lindquist NG, Larsson BS, Stjernschantz J. Increased pigmentation of iridial melanocytes in primates induced by a prostaglandin analogue. Exp Eye Res 1999;68:431-6
   PubMed Web of Science ®Google Scholar
• Takagi Y, Nakajima T, Shimazaki A, Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, a san ocular hypotensive drug. Exp Eye Res 2004;74:767-76
   Google Scholar
• Redell MA, Yang DC, Lee VHL. The role of esterase activity in the ocular disposition of dipivalyl epinephrine in rabbits. Int J Pharm 1983;17:299-312
   Web of Science ®Google Scholar
• Stjernschantz J, Selen G, Sjoequist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PG F2alpha analogue. Adv Prostaglandin Thromboxane Leuket Res 1995;23:513-18
   PubMedGoogle Scholar
• Madhu C, Rix P, Nguyen T, Penetration of natural prostaglandins and their ester prodrugs and analogs. J Ocul Pharmacol Ther 1998;14:389-99
   PubMed Web of Science ®Google Scholar
• Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos 2009;37:1622-34
   PubMed Web of Science ®Google Scholar
• Nakajima T, Matsugi T, Goto W, New fluoroprostaglandin F2alpha derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotennsive agents. Biol Pharm Bull 2003;26:1691-5
   PubMed Web of Science ®Google Scholar
• Kashiwagi K, Tsukamoto K, Suzuki M, Tsukahara SJ. Effects of isopropyl unoprostone and latanoprost on melanogenesis in mouse epidermal melanocytes. Glaucoma 2002;11:57-64
   PubMed Web of Science ®Google Scholar
• Higaki K, Kamata K, Takeuchi M, Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits. Drug Metab Dispos 1995;23:35-43
   PubMed Web of Science ®Google Scholar
• Sjoequist B, Basu S, Byding P, The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit. Drug Metab Dispos 1998;26:745-54
   PubMed Web of Science ®Google Scholar
• Kanamori A, Naka M, Fukuda M, Tafluprost protects rat retinal ganglion cells form apoptosis in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol 2009;247:1353-60
   PubMed Web of Science ®Google Scholar
• Sutton A, Gilvarry A, Ropo A. A comparative, placebo controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males. J Ocul Pharmacol Ther 2007;23:359-65
   PubMed Web of Science ®Google Scholar
• Sutton A, Gouws P, Ropo A. Tafluprost, a new potent prostanois receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers. Int J Clin Pharmacol Ther 2008;46:400-6
   PubMed Web of Science ®Google Scholar
• Uusitalo HMT, Pillunat LE, Baoudouin C, Phase III, 24-month study investigating the efficacy and safety of tafluprost vs latanoprost in patients with open-angle glaucoma or ocular hypertension. Acta Ophthalmol 2008;88:12-19
   Web of Science ®Google Scholar
• Egorov E, Ropo A. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol 2009;19:214-22
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Kaarniratanta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl 2008;242:7-13
   PubMedGoogle Scholar
• Aihara M. Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2010;4:163-70
   PubMedGoogle Scholar
• Traverso CE, Ropo A, Papadia M, Uusiatlo H. A phase II study in the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost. J Ocul Pharmacol Ther 2010;26:97-104
   PubMed Web of Science ®Google Scholar
• Kuwayama Y, Komemusi S. Phase III confirmatory study of 0.0015% DE-085 (Tafluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. Atarashii Ganka 2008;25:1595-602
   Google Scholar
• Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol 2010;88:12-19
   PubMed Web of Science ®Google Scholar
• Hamacher T, Airaksinen J, Saarela V, Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophtalmol Suppl (Oxf) 2008;242:14-19
   PubMedGoogle Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003;25:1172-85
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffe N, Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010;88:329-36
   PubMed Web of Science ®Google Scholar
• Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin 2010;26:195-213
   Web of Science ®Google Scholar
• Dogan AS, Orhan M, Soylemezoglu F, Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Exp Ophthalmol 2004;32:62-6
   PubMed Web of Science ®Google Scholar
• Hamard P, Blondin C, Debbasch C, In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells. Graefes Arch Clin Exp Ophthalmol 2003;241:1037-43
   PubMed Web of Science ®Google Scholar
• Blondin C, Hamard P, Cholley B, In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res 2003;27:253-9
   PubMed Web of Science ®Google Scholar